Hypoglycemia as a sign of paraneoplastic syndrome in a patient with pleural fibroma

Hypoglycemia as a sign of paraneoplastic syndrome in a patient with pleural fibroma

Authors

  • Ivana Sagova Department of Internal Medicine I Jessenius Medical Faculty of Comenius University and University Hospital Martin Kollárová 2 036 59 Martin
  • Daniela Kantárová
  • Matey Stancik
  • Adriana Klimentová
  • Jurina Sadloňová,
  • Marian Mokáň

Keywords:

hypoglycemia, insulin growth factor 2, non-islet cell tumors, paraneoplastic syndrome, therapy

Abstract

Paraneoplastic syndrome has a wide range of symptoms and fasting hypoglycemia is one of its possible clinical manifestations. It is mostly caused by insulinomas and non-islet cell tumors (large mesenchymal tumors account for more than a half of all neoplasms associated with hypoglycemia). Clinical features may vary and typical laboratory features of paraneoplastic hypoglycemia includes low level of fasting glucose and C-peptide, low  insulin growth factor 1 (IGF1) and elevated level of “big” insulin growth factor 2 (IGF2). The increased IGF2 : IGF1 ratio is considered to be pathognomic for this diagnosis. Although paraneoplastic hypoglycemia is mostly present in patients with the already diagnosed malignancy, it is necessary to consider this opportunity in patients having unclear and inexplicable hypoglycemia.  The adequate treatment can significantly reduce the symptoms and improve the quality of life.

Downloads

Published

2015-11-15

How to Cite

1.
Sagova I, Kantárová D, Stancik M, Klimentová A, Sadloňová, J, Mokáň M. Hypoglycemia as a sign of paraneoplastic syndrome in a patient with pleural fibroma. Eur J Oncol Env Hea [Internet]. 2015 Nov. 15 [cited 2025 Apr. 2];20(2):114-20. Available from: https://mattioli1885journals.com/index.php/EJOEH/article/view/3465